Abstract
Dendritic cells can take up exogenous tumor antigens and present their antigenic epitopes to CD8þ T cells (TCD8þ), a process called cross-presentation. Cross-presentation is especially important in antitumor immunity because tumor cells, although carrying tumor antigens, do not activate naive T cells efficiently because of a lack of co-stimulatory molecules. Our group has
recently shown that influenza A virus (IAV) infection of allogeneic cells lead to enhanced cross-priming of TCD8þ specific to cellular antigens. To develop this into a potential vaccine strategy, in this study, we have systematically investigated the numbers of allogeneic cells infected by IAV, IAV doses and their infectious activity, the length of in vitro infection and other associated factors. We have defined the optimal immune-enhancing conditions and we have also shown in vivo that such enhanced cross-priming did lead to enhanced tumor protection. The knowledge should be useful for developing more robust cancer vaccine.
recently shown that influenza A virus (IAV) infection of allogeneic cells lead to enhanced cross-priming of TCD8þ specific to cellular antigens. To develop this into a potential vaccine strategy, in this study, we have systematically investigated the numbers of allogeneic cells infected by IAV, IAV doses and their infectious activity, the length of in vitro infection and other associated factors. We have defined the optimal immune-enhancing conditions and we have also shown in vivo that such enhanced cross-priming did lead to enhanced tumor protection. The knowledge should be useful for developing more robust cancer vaccine.
Original language | English |
---|---|
Pages (from-to) | 576-582 |
Journal | Immunology and Cell Biology |
Volume | 91 |
Issue number | 9 |
Early online date | 10 Sep 2013 |
DOIs | |
Publication status | Published - Oct 2013 |